Zobrazeno 1 - 10
of 142
pro vyhledávání: '"E. Kyriakopoulos"'
Autor:
Rocio Diaz Escarcega, Vijay Kumar M. J., Vasilia E. Kyriakopoulos, Guadalupe J. Ortiz, Aaron M. Gusdon, Huihui Fan, Pedram Peesh, Maria P. Blasco Conesa, Gabriela Delevati Colpo, Hilda W. Ahnstedt, Lucy Couture, Stella H. Kim, Miriam Hinojosa, Christine M. Farrell, Sean P. Marrelli, Akihiko Urayama, Bhanu P. Ganesh, Paul E. Schulz, Louise D. McCullough, Andrey S. Tsvetkov
Publikováno v:
Neurobiology of Disease, Vol 204, Iss , Pp 106747- (2025)
Alzheimer's disease (AD) affects more women than men. Although women live longer than men, it is not longevity alone, but other factors, including metabolic changes, that contribute to the higher risk of AD in women. Metabolic pathways have been impl
Externí odkaz:
https://doaj.org/article/169323e61f4244ec9171e8061bea4513
Autor:
Douglas G McNeel, Glenn Liu, Ellen Wargowski, Hamid Emamekhoo, Jens C Eickhoff, Laura E Johnson, Christos E Kyriakopoulos, Tommaso P Tonelli
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Purpose We have previously reported that a plasmid DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) had greater clinical activity when given in combination with pembrolizumab to patients with metastatic, castration-resistant prostate cancer.
Externí odkaz:
https://doaj.org/article/2f642e066f094a72bc45cb6a957b74fd
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Poly-ADP ribose polymerase inhibitors (PARPi) are an emerging therapeutic option for the treatment of prostate cancer. Their primary mechanism of action is via induction of synthetic lethality in cells with underlying deficiencies in homologous recom
Externí odkaz:
https://doaj.org/article/ec1039754dd548bf89168a435ead7aa0
Autor:
Shuang G. Zhao, Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh, Zachery D. Schultz, Rory M. Bade, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Camila I. Hernandez, Serena K. Wolfe, Richel D. Mayberry, Hannah M. Krause, Matt Bootsma, Kyle T. Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Christos E. Kyriakopoulos, David Kosoff, Xiao X. Wei, John Floberg, Nan Sethakorn, Marina Sharifi, Paul M. Harari, Wei Huang, Himisha Beltran, Toni K. Choueiri, Howard I. Scher, Dana E. Rathkopf, Susan Halabi, Andrew J. Armstrong, David J. Beebe, Menggang Yu, Kaitlin E. Sundling, Mary-Ellen Taplin, Joshua M. Lang
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 21 (2022)
Background Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer.Methods We performed analytical validation of a Circulating Tumor Cell (CTC) multiplex
Externí odkaz:
https://doaj.org/article/ec5e2f5145314e94b0c25808c0d5eee0
Autor:
Douglas G McNeel, Glenn Liu, Joshua M Lang, Ellen Wargowski, Hamid Emamekhoo, Mary Jane Brennan, Jens C Eickhoff, Laura E Johnson, Christos E Kyriakopoulos
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background We previously reported a trial using a DNA vaccine encoding prostatic acid phosphatase (MVI-816, pTVG-HP), given over 12 weeks concurrently or sequentially with pembrolizumab, in patients with mCRPC. We report the final analysis of this tr
Externí odkaz:
https://doaj.org/article/83dffdc4eece4620a9c1a0e189a455e3
Publikováno v:
Urology Case Reports, Vol 38, Iss , Pp 101720- (2021)
Brief abstract: Castleman's disease (CD) is an uncommon lymphoproliferative process that can present concurrent to other solid organ malignancy, especially in selected populations. Concomitant CD and renal cell carcinoma (RCC) are challenging in term
Externí odkaz:
https://doaj.org/article/7b36597c8313485a84b81361576e7bf1
Autor:
Jamie M. Sperger, Kyle T. Helzer, Charlotte N. Stahlfeld, Dawei Jiang, Anupama Singh, Katherine R. Kaufmann, David J. Niles, Erika Heninger, Nicholas R. Rydzewski, Liguo Wang, Liewei Wang, Rendong Yang, Yanan Ren, Jonathan W. Engle, Peng Huang, Christos E. Kyriakopoulos, Susan F. Slovin, Howard R. Soule, Shuang G. Zhao, Manish Kohli, Scott T. Tagawa, Weibo Cai, Scott M. Dehm, Joshua M. Lang
Publikováno v:
Clinical Cancer Research. :OF1-OF12
Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) frequently develop resistance to androgen receptor signaling inhibitor (ARSI) treatment; therefore, new therapies are needed. Trophoblastic cell-surface antigen (TROP-2) is a t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a6499da8242b249df8a969609dc3f5c
https://doi.org/10.1158/1078-0432.ccr-22-1305
https://doi.org/10.1158/1078-0432.ccr-22-1305
Autor:
Elizabeth Pan, Wanling Xie, Archana Ajmera, Arlene Araneta, Christina Jamieson, Edmund Folefac, Arif Hussain, Christos E. Kyriakopoulos, Adam Olson, Mamta Parikh, Rahul Parikh, Biren Saraiya, S. Percy Ivy, Eliezer M. Van Allen, Neal I. Lindeman, Bose S. Kochupurakkal, Geoffrey I. Shapiro, Rana R. McKay
Publikováno v:
Molecular Cancer Therapeutics. 22:511-518
Given that radium-223 is a radiopharmaceutical that induces DNA damage, and olaparib is a PARP inhibitor that interferes with DNA repair mechanisms, we hypothesized their synergy in metastatic castration-resistant prostate cancer (mCRPC). We sought t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd08ddb7e908aa341fa6a73a7134dded
https://doi.org/10.1158/1535-7163.mct-22-0583
https://doi.org/10.1158/1535-7163.mct-22-0583
Autor:
Matthew Bootsma, Rana R. McKay, Hamid Emamekhoo, Rory M. Bade, Jennifer L. Schehr, Matthew C. Mannino, Anupama Singh, Serena K. Wolfe, Zachery D. Schultz, Jamie Sperger, Wanling Xie, Sabina Signoretti, Christos E. Kyriakopoulos, David Kosoff, Edwin J. Abel, Kyle T. Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Michael Bassetti, John Floberg, Menggang Yu, Nan Sethakorn, Marina Sharifi, Paul M. Harari, Toni K. Choueiri, Joshua M. Lang, Shuang G. Zhao
Publikováno v:
Journal of Clinical Oncology. 40:3633-3641
PURPOSE Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance. This is particularly important in the context of immunotherapies, which target key imm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::425c347c3d98d5fbfc73d8d02cd6583d
https://doi.org/10.1200/jco.22.00219
https://doi.org/10.1200/jco.22.00219
Figure S3 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Autor:
Joshua M. Lang, Scott M. Dehm, Weibo Cai, Scott T. Tagawa, Manish Kohli, Shuang G. Zhao, Howard R. Soule, Susan F. Slovin, Christos E. Kyriakopoulos, Peng Huang, Jonathan W. Engle, Yanan Ren, Rendong Yang, Liewei Wang, Liguo Wang, Nicholas R. Rydzewski, Erika Heninger, David J. Niles, Katherine R. Kaufmann, Anupama Singh, Dawei Jiang, Charlotte N. Stahlfeld, Kyle T. Helzer, Jamie M. Sperger
Figure S3. Scatter plot of gene expression for genes shown in Figure 3D isolated from matched anti-EPCAM vs anti-TROP-2 captured CTCs at the same timepoint.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22d11482e4e2bb0f4410e4af5cb5086e
https://doi.org/10.1158/1078-0432.22709368.v1
https://doi.org/10.1158/1078-0432.22709368.v1
